Your session is about to expire
← Back to Search
Chemotherapy Combo for Desmoplastic Small Round Cell Tumor
Study Summary
This trial is testing a new combination of drugs to treat DSRCT, a rare and aggressive cancer. The goal is to see if the new combo is effective and has fewer side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the ultimate aim of this experiment?
"The primary objective of this two-year clinical trial is to evaluate the tolerability, while secondary outcomes include assessing time to progression and survival rates with irinotecan, temozolomide and bevacizumab treatment in patients with DSRCT. Additionally, 18FDG PET-CT will be used as an early indicator for response evaluation among those who have measurable or evaluable disease."
Are seniors over 45 years of age able to participate in this trial?
"Participants in this trial must range from one year to 29 years of age. Seperately, there are 235 trials aimed at citizens below 18 and 1054 for those over 65."
Has research been conducted to ascertain whether a combination of irinotecan, temozolomide and bevacizumab could augment the effects of high-dosage alkylator therapy?
"Presently, 738 trials evaluating the combination of irinotecan, temozolomide and bevacizumab with an alkylator-based regimen are still underway; 149 of these have progressed to Phase 3. The majority of sites conducting clinical research on this subject matter is located in Houston, Texas. Nevertheless, there are 27321 healthcare institutions around United States running experiments for irinotecan, temozolomide and bevacizumab incorporated into an existing schedule of high dose alkylator."
What is the maximum capacity of people taking part in this research?
"At this time, recruitment for the aforementioned trial has concluded. The study was first posted on August 1st 2010 and last modified on September 1st 2022. For those seeking alternative studies; 451 trials are presently recruiting patients with sarcoma, as well 738 studies focusing on irinotecan, temozolomide and bevacizumab integrated into a pre-existing schedule of high dose alkylators have openings available."
Might I have the opportunity to partake in this research project?
"This trial is seeking 15 patients, aged between 1 and 29 years old, with a new diagnosis of DSRCT. Additionally, candidates must have an Absolute Neutrophil Count at or above 1000/mm3; Platelet count higher than 100000/mytm3; Creatinine Clearance level significantly greater than 70ml/min/1.73 m2 ; Total Bilirubin under 1.5 times the ULN for age; AST not exceeding 2.5 times the ULN for age (with no evidence of hepatic involvement); normal cardiac function as measured by Shortening Fraction over 28% on e"
What type of treatment regimen is irinotecan, temozolomide, and bevacizumab most frequently used to supplement high dose alkylator therapy?
"Soft tissue sarcoma (STS) typically responds to a treatment schedule incorporating irinotecan, temozolomide and bevacizumab alongside high dosage alkylators. This approach can also prove effective for other ailments such as recurrent platinum-sensitive epithelial ovarian cancer, malignant neoplasms and refractory Ewing sarcoma."
Are there vacancies available to individuals looking to join the clinical trial?
"No, this clinical trial is not actively recruiting at the moment. Initially posted on August 1st 2010 and last edited September 1st 2022, it has since been closed for new participants. However, there are 1189 other trials that still require enrolment."
Share this study with friends
Copy Link
Messenger